Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed
- 1 May 2016
- journal article
- review article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 196, 225-233
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*International Journal of Neuropsychopharmacology, 2012
- Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?International Journal Of Clinical Practice, 2012
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- How to Obtain NNT from Cohen's d: Comparison of Two MethodsPLOS ONE, 2011
- A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2011
- Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or HarmedPostgraduate Medicine, 2010
- Treatment-Emergent Sexual Dysfunction Related to AntidepressantsJournal of Clinical Psychopharmacology, 2009
- Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2009
- Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorderCurrent Medical Research and Opinion, 2007
- Efficacy and Tolerability of Once-Daily Venlafaxine Extended Release (XR) in Outpatients With Major DepressionThe Journal of Clinical Psychiatry, 1997